公开(公告)号：WO2019140435A1

公开(公告)日：2019-07-18

申请号：PCT/US2019/013617

申请日：2019-01-15

Applicant: STC. UNM

Inventor： CALHOUN, Vince ,  SUI, Jing

IPC: A61B5/055 ,  G06T7/45

Abstract: The present invention is directed to a system and methods of predicting undiagnosed mental disorders in a patient and determining the best medication-class treatment for the mental disorder through the analysis of functional magnetic resonance imaging of functional connectivity of the brain representative of a certain mental disorder.

公开(公告)号：WO2019094824A1

公开(公告)日：2019-05-16

申请号：PCT/US2018/060169

申请日：2018-11-09

Applicant: STC. UNM ,  SHAW, Richard ,  LUAN, Shuang

Inventor： SHAW, Richard ,  LUAN, Shuang

IPC: A61N5/10 ,  H05H6/00 ,  H05H7/12

Abstract: Described are devices, systems, and methods for modulating the spectral energy distribution produced by an x-ray source via control of the energy of the x-ray-generating electron beam, e.g., for energy-modulated radiation therapy or other purposes. In some embodiments, such energy modulation is achieved by an add-on device to a linear accelerator. Also disclosed are computational methods and computer program products for planning energy-modulated therapy.

公开(公告)号：WO2018022154A2

公开(公告)日：2018-02-01

申请号：PCT/US2017/029180

申请日：2017-04-24

Applicant: STC. UNM

Inventor： BRUECK, Steven, R.J. ,  FEEZELL, Daniel ,  RANDALL, John ,  BUSANI, Tito ,  BALLARD, Joshua, B. ,  BEHZADIRAD, Mahmoud ,  RISHINARAMANGALAM, Ashwin Krishnan

CPC classification number: G01Q60/16 ,  B82B3/0004 ,  G01Q70/06 ,  G01Q70/14 ,  G01Q80/00 ,  G03F7/0002

Abstract: Provided is a composite metal-wide-bandgap semiconductor tip for scanning tunneling microscopy and/or scanning, tunneling lithography, a method of forming, and a method for using the composite metal-wide-bandgap semiconductor tip.

公开(公告)号：WO2017066795A2

公开(公告)日：2017-04-20

申请号：PCT/US2016/057407

申请日：2016-10-17

Applicant: STC. UNM

Inventor： HAN, Sang Eon ,  HAN, Sang M.

IPC: F28F3/00

CPC classification number: F28F13/185 ,  F24S70/20 ,  F28F2245/06

Abstract: The present prevention provides a surface coating for cooling a surface by light scattering comprising a plurality of successive layers, each of the layers may be comprised of a plurality of spheres arranged to form a structure comprised of packed spheres. Each layer may have a different arrangement of packed spheres to create to a different light scattering property in each of the layers. The coating of the structures may also be formed by randomly packed spheres and the spheres may have a uniform diameter.

Abstract translation: 本发明防止了通过包括多个连续层的光散射来冷却表面的表面涂层，每个层可以包括多个球体，所述球体被布置以形成由填充球体组成的结构 。 每层可以具有不同的填充球的排列，以在每个层中产生不同的光散射特性。 结构的涂层也可以由随机填充的球体形成，并且球体可以具有均匀的直径。

公开(公告)号：WO2016154522A1

公开(公告)日：2016-09-29

申请号：PCT/US2016/024174

申请日：2016-03-25

Applicant: STC. UNM ,  BHASKAR, Kiran ,  MAPHIS, Nicole ,  PEABODY, David, S. ,  CHACKERIAN, Bryce ,  PEABODY, Julianne ,  CROSSEY, Erin

Inventor： BHASKAR, Kiran ,  MAPHIS, Nicole ,  PEABODY, David, S. ,  CHACKERIAN, Bryce ,  PEABODY, Julianne ,  CROSSEY, Erin

IPC: A61K39/00 ,  A61P25/00 ,  A61P25/16 ,  C12N15/12 ,  C12N15/63

CPC classification number: A61K39/0007 ,  A01K67/0278 ,  A01K2217/056 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/0306 ,  A01K2267/0312 ,  A01K2267/0318 ,  A01K2267/0368 ,  A61K2039/5258 ,  A61K2039/575 ,  C12N7/00 ,  C12N2795/18123 ,  C12N2795/18134 ,  C12N2795/18171

Abstract: This disclosure describes, in one aspect, immunogens effective for treating and/or diagnosing tauopathy, and immunotherapeutic compositions and methods involving those immunogens. Generally, the immunogen includes an antigen presentation component and a microtubule-associated tau protein (MAPT) component linked to at least a portion of the antigen presentation component. This disclosure describes, in another aspect, a transgenic mouse. Generally, the transgenic mouse possesses brain cells that have a polynucleotide that encodes human microtubule-associated protein tau (MAPT). The polynucleotide further exhibits a deletion of at least a portion of endogenous mouse MAPT. The transgenic mouse also includes a forebrain neuron-specific deletion of a polynucleotide that encodes Myeloid Differentiation Primary Response Gene 88 (MyD88). In a further aspect, this disclosure describes a method of producing the transgenic mouse.

Abstract translation: 本公开一方面描述了有效治疗和/或诊断tau病变的免疫原，以及涉及这些免疫原的免疫治疗组合物和方法。 通常，免疫原包括与至少一部分抗原呈递组分连接的抗原呈递组分和与微管相关的tau蛋白（MAPT）组分。 本公开在另一方面描述了转基因小鼠。 通常，转基因小鼠具有具有编码人微管相关蛋白tau（MAPT）的多核苷酸的脑细胞。 多核苷酸进一步显示至少部分内源小鼠MAPT的缺失。 转基因小鼠还包括编码骨髓分化原发性反应基因88（MyD88）的多核苷酸的前脑神经元特异性缺失。 在另一方面，本公开描述了生产转基因小鼠的方法。

公开(公告)号：WO2015126922A2

公开(公告)日：2015-08-27

申请号：PCT/US2015/016349

申请日：2015-02-18

Applicant: STC. UNM

Inventor： TIMMINS, Graham ,  CHOI, Seong, Won ,  SILKS, Louis, Pete A.

IPC: G01N33/532

CPC classification number: G01N33/58 ,  A61K49/0004 ,  G01N33/5695 ,  G01N2333/35 ,  G01N2458/15 ,  G01N2800/52

Abstract: In one embodiment, the invention provides methods of identifying the sensitivity and resistance to therapeutic drug regimens in a subject who suffers from, or who is suspected of suffering from, a Mycobacterium infection, the method comprising administering (1) isotopically labeled Pretomanid and/or Delaminid, or (2) isotopically labeled ethionamide and/or prothionamide, or (3) isotopically labeled pyrazinamide, or (4) isotopically-labeled isoniazid to the subject and thereafter measuring levels in a subject-derived sample of one or more isotopically-labeled markers corresponding to Mycobacterium-actiwated drug metabolites or degradation products, wherein the absence of detectable levels of Mycobacterium-activated drug metabolites or degradation products indicates either that the subject does not suffer from a Mycobacterium infection or suffers from a Mycobacterium infection which is resistant to treatment with the administered drug regimen.

Abstract translation: 在一个实施方案中，本发明提供鉴定患有或疑似患有分枝杆菌感染的受试者的治疗药物方案的敏感性和抗性的方法，所述方法包括施用（1）同位素标记的假单胞菌素和/或 （2）同位素标记的乙硫氨酰胺和/或丙硫氨酰胺，或（3）同位素标记的吡嗪酰胺或（4）同位素标记的异烟肼，然后测定受试者衍生的样品中一种或多种同位素标记 对应于分枝杆菌活化的药物代谢物或降解产物的标记，其中不存在可检测水平的分枝杆菌激活的药物代谢物或降解产物表明受试者不患有分枝杆菌感染或遭受耐受治疗的分枝杆菌感染 与施用的药物方案。

公开(公告)号：WO2015061360A1

公开(公告)日：2015-04-30

申请号：PCT/US2014/061637

申请日：2014-10-21

Applicant: STC. UNM ,  MAMMOLI, Andrea, A. ,  LAVROVA, Olga ,  ARELLANO, Brian ,  CHENG, Feng ,  GREENWOOD, Wesley ,  HAWKINS, Jonathan ,  WILLARD, Steve

Inventor： MAMMOLI, Andrea, A. ,  LAVROVA, Olga ,  ARELLANO, Brian ,  CHENG, Feng ,  GREENWOOD, Wesley ,  HAWKINS, Jonathan ,  WILLARD, Steve

IPC: H02J3/36 ,  H02J3/38 ,  H02S40/38

CPC classification number: H02J3/383 ,  H02J3/12 ,  H02J3/32 ,  H02J3/386 ,  H02J7/0068 ,  H02M3/04 ,  H02M7/44 ,  H02S40/38 ,  Y02E10/563 ,  Y02E10/566 ,  Y02E70/30

Abstract: The present invention is an apparatus and method for delivering energy using a renewable resource. The method includes providing a photovoltaic energy source and applying energy storage to the photovoltaic energy source via a battery storage unit. The energy output from the photovoltaic energy source and the battery system is controlled using a battery control system. The battery control system predicts peak load, develops a schedule that includes when to begin discharging power and when to stop discharging power, shifts power to the battery storage unit when excess power is available, and prioritizes the functionality of the battery storage unit and the photovoltaic energy source.

Abstract translation: 本发明是一种使用可再生资源传递能量的装置和方法。 该方法包括提供光伏能源并且经由电池存储单元向光伏能源施加能量存储。 使用电池控制系统控制来自光伏能源和电池系统的能量输出。 电池控制系统预测峰值负载，制定包括什么时候开始放电并且何时停止放电的时间表，在多余电力可用时将电力转移到电池存储单元，并且优先考虑电池存储单元和光伏的功能 能量源。

公开(公告)号：WO2015042279A1

公开(公告)日：2015-03-26

申请号：PCT/US2014/056342

申请日：2014-09-18

Applicant: STC. UNM ,  SANDIA CORPORATION

Inventor： BRINKER, C., Jeffrey ,  LIN, Yu-shen

IPC: A61K9/127 ,  A61K31/7088 ,  A61K38/00 ,  B82Y5/00

CPC classification number: A61K9/1271 ,  A61K9/14 ,  A61K9/5115 ,  A61K9/5123 ,  A61K31/7088 ,  A61K38/16 ,  A61K38/43 ,  A61K39/395 ,  B82Y5/00 ,  B82Y15/00 ,  C12N15/88

Abstract: In one aspect, the invention provides novel monodisperse, colloidally-stable, torroidal mesoporous silica nanoparticles (TMSNPs) which are synthesized from ellipsoid-shaped mesoporous silica nanoparticles (MSNPs) which are prepared using an ammonia base- catalyzed method under a low surfactant conditions. Significantly, the TMSNPs can be loaded simultaneously with a small molecule active agent, a siRNA, a mRNA, a plasmid and other cargo and can be used in the diagnosis and/or treatment of a variety of disorders, including a cancer, a bacterial infection and/or a viral infection, among others. Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.

Abstract translation: 一方面，本发明提供了在低表面活性剂条件下使用氨碱催化法制备的由椭球形介孔二氧化硅纳米粒子（MSNP）合成的新型单分散，胶体稳定的环状介孔二氧化硅纳米粒子（TMSNP）。 值得注意的是，TMSNPs可以与小分子活性剂，siRNA，mRNA，质粒和其他货物同时加载，并且可以用于诊断和/或治疗各种疾病，包括癌症，细菌感染 和/或病毒感染等。 还提供了相关的原细胞，药物组合物和治疗和诊断方法。

公开(公告)号：WO2011066521A2

公开(公告)日：2011-06-03

申请号：PCT/US2010/058282

申请日：2010-11-30

Applicant: STC. UNM ,  MIAO, Yubin ,  GUO, Haixun

Inventor： MIAO, Yubin ,  GUO, Haixun

IPC: C07K7/64 ,  A61K38/12 ,  C07K7/00 ,  G01N33/574 ,  A61P35/00

CPC classification number: C07K14/68 ,  A61K38/00 ,  A61K45/06 ,  A61K51/08 ,  A61K51/086 ,  A61K51/088 ,  C07K7/54

Abstract: The present invention is directed to novel non-invasive diagnostic tools/compounds to image cancers, especially, melanoma, including metastatic melanoma in vivo. The present compounds exhibit enhanced uptake in cancerous cells and tissue and decreased renal uptake in kidney, evidencing favorable pharmacokinetics of compounds of the present invention. The compounds according to the present invention represent an advance in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are also useful for initiating therapy for melanoma as well as monitor patients' response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.

Abstract translation: 本发明涉及用于成像癌症的新型非侵入性诊断工具/化合物，特别是黑素瘤，包括体内转移性黑素瘤。 本发明化合物在癌细胞和组织中表现出增强的摄取，并且减少了肾中的肾摄取，证明了本发明化合物的有利的药代动力学。 根据本发明的化合物代表使用非侵入性分子成像技术在黑色素瘤的诊断和治疗中的进展，包括转移性黑素瘤。 本发明的新型探针也可用于开始黑色素瘤的治疗以及监测患者对化疗治疗的反应和用于治疗黑素瘤/转移性黑色素瘤的其它干预或治疗。 根据本发明的化合物可以用作许多病症和疾病状态的诊断工具以及用于治疗这些病症和疾病状态的治疗剂。

公开(公告)号：WO2010068229A1

公开(公告)日：2010-06-17

申请号：PCT/US2009/004310

申请日：2009-07-24

Applicant: STC. UNM ,  HIGGIN, Roslyn

Inventor： HIGGIN, Roslyn

IPC: B01D65/02 ,  C02F1/44

CPC classification number: B01D61/025 ,  B01D65/08 ,  B01D2321/168

Abstract: A method of controlling fouling of a reverse osmosis membrane disposed in an aqueous medium by an inorganic foulant involves providing a fouling control agent comprising an acidic polysaccharide such as alginic acid fouling control agent dissolved in the aqueous medium in an amount effective to reduce, reverse, or prevent fouling by an inorganic foulant.

Abstract translation: 通过无机污垢剂控制设置在水性介质中的反渗透膜的结垢控制方法包括提供一种污垢控制剂，其包含溶解在水性介质中的酸性多糖如海藻酸结垢控制剂，其量可有效地减少，反向， 或防止无机污垢的结垢。